Literature DB >> 3032884

Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.

P Van der Auwera, P Joly.   

Abstract

The bactericidal interactions in vitro of two antibiotics active at the cell wall (teicoplanin and vancomycin) or two inhibitors of DNA gyrase (coumermycin and ciprofloxacin) combined with two inhibitors of protein synthesis (rifampicin and LM 427) were assessed against five Staphylococcus aureus strains. The S. aureus isolates included two oxacillin-sensitive and three oxacillin-resistant strains. The concentrations tested covered the range usually obtained in the serum with recommended doses. Coumermycin + rifampicin or LM 427, and ciprofloxacin + rifampicin or LM 427 were antagonistic when the concentration of either drug was higher than the MIC, and additive when sub-MIC concentrations were tested. Teicoplanin or vancomycin + rifampicin or LM 427 produced variable results. Of the synergic combinations, 14 of 15 included teicoplanin. Of the antagonistic combinations, 20 of 33 included LM 427. Antagonism with LM 427 was due to the higher intrinsic activity of LM 427 alone than teicoplanin, vancomycin or rifampicin. Teicoplanin (20 mg/l) + rifampicin or LM 427 (1 mg/l) was synergic (9/10).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032884     DOI: 10.1093/jac/19.3.313

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.

Authors:  Samuel A Shelburne; Daniel M Musher; Kristina Hulten; Heather Ceasar; Michael Y Lu; Imran Bhaila; Richard J Hamill
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Failure of time-kill synergy studies using subinhibitory antimicrobial concentrations to predict in vivo antagonism of cephalosporin-rifampin combinations against Staphylococcus aureus.

Authors:  C M Brandt; M S Rouse; B M Tallan; W R Wilson; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.

Authors:  M P Weinstein; R G Deeter; K A Swanson; J S Gross
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.

Authors:  J Fortún; J A Pérez-Molina; M T Añón; J Martínez-Beltrán; E Loza; A Guerrero
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

6.  Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin.

Authors:  C A Day; M L Marceau-Day; D F Day
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 7.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

9.  Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.